Glacier EMS

Trazodone for Depression: From Diagnosis to Follow-Up

Adult depression treatment pathway with assessment and follow-up records

Adult depression · Labeled-use context

Trazodone for Depression: From Diagnosis to Follow-Up

Trazodone is labeled in the United States for major depressive disorder in adults. Using it well starts with a diagnosis, not a symptom checklist or product request. The treatment decision considers severity, function, prior response, psychotherapy, medication options, safety history and how benefit and adverse effects will be followed.

Desyrel and trazodone pharmacy packaging for Trazodone for Depression: From Diagnosis to Follow-Up
Adult MDD labelDiagnosis requiredOptions comparedFunction monitored
Steven Chan, MD, MBA

Medically reviewed by

Steven Chan, MD, MBA

Psychiatry, addiction medicine and clinical informatics

Medical review completed August 27, 2026

View Glacier contributor profile

Build a depression treatment decision

1. Assess symptoms and function

Describe duration, severity, daily impairment and urgent risk.

2. Check diagnostic alternatives

Review bipolar symptoms, substances, medical causes and other conditions.

3. Compare treatment choices

Discuss psychotherapy, medicines, combined care, preferences and access.

4. Measure the plan

Track mood, interest, function, adverse effects and safety concerns.

Questions that shape treatment fit

A decision table for adult depression care
Question Why it matters Follow-up
MDD diagnosis Matches labeled use Reassess symptoms
Prior response Shows benefit or burden Compare changes
Bipolar clues May alter treatment Monitor activation
Daily function Measures meaningful change Track goals

The diagnosis is more than feeling sad

NIMH describes depression as persistent symptoms that affect how a person feels, thinks and handles daily activities. A clinician asks about mood, interest, energy, concentration, sleep, appetite, guilt, hopelessness and thoughts of death, while also considering medical conditions and medicines that can cause similar changes.

Trazodone has a labeled adult depression role

The DailyMed label identifies trazodone hydrochloride tablets for major depressive disorder in adults. It also states that trazodone is not approved for pediatric patients. The indication establishes what has been reviewed in the label; it does not establish that trazodone is the best first choice for every adult. For more detail on this decision, review trazodone uses.

Past high-energy periods can alter the diagnosis

The label directs screening for personal or family history of bipolar disorder, mania or hypomania before antidepressant treatment. Reduced need for sleep, unusually elevated or irritable mood, racing thoughts and risky behavior are important history. Treating a bipolar presentation as unipolar depression can create avoidable risk.

Psychotherapy and medication are both real pathways

The VA/DoD MDD guideline and NIMH describe psychotherapy, pharmacotherapy and combined care as treatment approaches. The choice can reflect severity, recurrence, prior response, preference, access, pregnancy context, adverse-effect priorities and urgency. Discussing alternatives does not weaken a medication plan; it makes the decision more complete.

Treatment goals should include function

A symptom may improve without restoring work, relationships, self-care or engagement. Follow-up can therefore track both symptom change and practical function. The clinician also checks adherence, cost, sedation, dizziness, sexual effects and new medicines. These observations can support continuing, adjusting or replacing the plan. A related clinical question is covered in trazodone clinical review online.

Early worsening and activation need a route for contact

The antidepressant boxed warning and precautions make mood monitoring essential, especially around treatment changes. The patient and trusted supports should know how to report worsening depression, suicidal thinking, severe restlessness, agitation or signs of mania. A follow-up date alone is not enough if symptoms become urgent sooner.

A partial response calls for reassessment, not improvisation

If some symptoms improve while others persist, the clinician can revisit adherence, diagnosis, treatment duration, adverse effects and psychosocial stressors. Options may include psychotherapy, medication adjustment, a switch, combined care or specialty input. Doubling, skipping or adding another product without guidance makes the response harder to interpret.

The patient’s preferences are clinical information

Preferences about psychotherapy, medication burden, sexual effects, sedation, pregnancy plans, work schedule, pharmacy access and follow-up can alter which reasonable option is sustainable. Shared decision-making does not mean granting a requested prescription automatically. It means explaining the evidence and tradeoffs clearly enough that the patient can participate in a safe plan.

Questions readers ask after this review

Is trazodone approved for depression?

Yes. The checked U.S. label indicates trazodone hydrochloride tablets for major depressive disorder in adults.

Does low mood automatically mean MDD?

No. Duration, symptom pattern, impairment, medical causes, substances and other diagnoses must be considered.

Why screen for bipolar disorder?

Antidepressants can activate mania or hypomania, and bipolar depression may require a different treatment plan.

Can psychotherapy be used with medication?

Yes. Depending on severity and history, psychotherapy, medication or combined care may be discussed.

How is progress measured?

Track symptoms, daily function, adverse effects, adherence, safety changes and whether the diagnosis still fits.

Primary and authoritative sources

Educational information for human care only. This page does not diagnose a condition, guarantee a prescription, select an individual dose, replace a clinician or provide veterinary advice.

Scroll to Top